Bristol-Myers Squibb: Progress On The Bridge, But The Patent Cliffs Remain (Rating Downgrade)

Bristol-Myers Squibb is downgraded to Hold as its current valuation appears optimistic ahead of looming patent cliffs. Read more on BMY stock here.